A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.

Julia Katharina Schwarze,Johnny Duerinck,Inès Dufait,Gil Awada,Samuel Klein,Lydia Fischbuch,Laura Seynaeve,Freya Vaeyens,Anne Rogiers,Hendrik Everaert,Anne-Marie Vanbinst,Alex Michotte,Bart Neyns

A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.

2020

Julia Katharina Schwarze
Johnny Duerinck
Inès Dufait
Gil Awada
Samuel Klein
Lydia Fischbuch
Laura Seynaeve
Freya Vaeyens
Anne Rogiers
Hendrik Everaert
Anne-Marie Vanbinst
Alex Michotte
Bart Neyns

2534Background: Intravenous (IV) administration of ipilimumab (IPI) and nivolumab (NIVO) has low activity in recurrent glioblastoma (rGB). Intratumoral (IT) and intracavitary (IC) administration of...

Keywords:

Oncology
recurrent glioblastoma
in patient
Ipilimumab
Internal medicine
Nivolumab
Phases of clinical research
Pathology
Medicine
low activity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations